SMS Pharmaceuticals clears second USFDA inspection at Hyderabad lab with zero observations
By Aman Shukla Published on June 25, 2025, 16:19 IST
SMS Pharmaceuticals has recently informed exchanges that the company successfully completed its second inspection by the United States Food and Drug Administration (USFDA) at its Central Laboratory Analytical Services in Gagillapur, Hyderabad.
The inspection, held from June 23 to June 25, 2025, concluded with zero Form 483 observations, reflecting the company's strong focus on quality and compliance.
This Central Lab is an independent analytical testing facility, and the clean inspection outcome reaffirms SMS Pharma's commitment to CGMP and GLP standards across all its units. The company continues to maintain world-class quality practices, ensuring trust and reliability in every aspect of its operations.
In the meantime, SMS Pharmaceuticals shares closed today at ₹239.00, after opening at ₹234.25. The stock touched an intraday high of ₹239.90 and a low of ₹234.25 during the session. The company's 52-week high stands at ₹398.00, while the 52-week low is ₹176.05.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
The J. M. Smucker Company (SJM) I Told Them Not To Buy Twinkies!, Says Jim Cramer
The J. M. Smucker Company (NYSE:SJM) is one of the . The J. M. Smucker Company (NYSE:SJM) is a major American food products company. As has been the case with other food companies, such as Pepsi, investors are worried about the firm suffering in the aftermath of the GLP-1 wave in America. The J. M. Smucker Company (NYSE:SJM)'s shares have lost 12.9% year-to-date primarily due to a disastrous 15.6% dip in June. The shares fell after the firm's latest earnings report disappointed investors on the guidance front. The J. M. Smucker Company (NYSE:SJM) guided $9 in midpoint full-year earnings while analysts had penciled in $10.26. In his remarks, Cramer discussed an overlooked factor behind the earnings disaster: '[After Faber pointed out the shares were down 6% and the firm had missed guidance] Yeah I didn't really uh, that was quite opaque . . it's not clear what it is. I'll tell you what is clear. 980 million dollar impairment charge for Hostess Twinkies bought for 5.6 billion at the beginning of what is called GLP-1. I told them not to do it!' The J. M. Smucker Company (NYSE:SJM)'s management warned about tariffs in its latest earnings call. Here is what they said: 'As a domestic food producer, we are relatively less exposed to tariffs compared to other industries. That said, the current U.S. tariff impact on green coffee is our largest exposure that we will manage on top of navigating record-high costs for the commodity. Green coffee is an unavailable natural resource that cannot be grown in the continental U.S. due to its reliance on a tropical climate. We currently purchase approximately 500 million pounds of green coffee annually, with the majority coming from Brazil and Vietnam, the 2 largest coffee producing countries. Outside of coffee, the vast majority of our U.S. production is sourced domestically. However, there is some sourcing of finished goods and ingredients that are subject to tariffs as things stand today. A wholesaler distributing peanut butter, fruit spreads and specialty spreads to a retailer. This has been factored into our outlook, and we are working to mitigate these cost increases through a combination of alternative sourcing strategies, supply chain optimization, and responsible pricing.' While we acknowledge the potential of SJM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
McDonald's Corporation (MCD): Those Who Downgrade The Stock Will Be 'Wrong,' Says Jim Cramer
McDonald's Corporation (NYSE:MCD) is one of the . McDonald's Corporation (NYSE:MCD) is a frequent feature of Cramer's morning show. The fast food giant's shares have lost 1.7% year-to-date primarily due to 5% since mid-June. McDonald's Corporation (NYSE:MCD), like other food companies, is at the risk of its business being disrupted or shrunk due to GLP-1 drugs as they help users control their hunger. The shares fell in June after a downgrade from Redburn. Commenting on stock downgrades, Cramer outlined: '[On a third downgrade based on a lower value proposition than before in case of a recession] They're gonna be wrong. They are gonna be wrong. Okay Kempczinski is under fire because of the chicken strips and then next week we'll all get chicken strips with the wraps. You want to see how ugly chicken strips are, they're ugly, they don't look like, I don't know what they look like. . .but I know that Chris will kill that if it doesn't sell . . . And people are really underrating Chris. He is a great CEO. McDonald's has a history of getting rid of CEOs if they don't work, getting rid of dishes if they don't work. Earlier, Cramer discussed Morgan Stanley and Loop Capital downgrading McDonald's Corporation (NYSE:MCD)'s stock: 'It amazes me that analysts refuse to learn from their mistakes that some stocks should not be taken off the buy list. Today, Morgan Stanley downgraded the stock of McDonald's, saying it's arguably too expensive and that it will probably not be insulated from some structural pressures on fast food. Now, with the stock at 25 times earnings, consensus estimate's too high. Morgan Stanley moved [it] to Equal Weight or Hold. [The] stock dropped $2 and 58 cents or 0.84% on that. A cook in a busy kitchen assembling cheeseburgers for orders. Listen, McDonald's is an amazing company. It didn't become amazing because it stuck with bad ideas… The strength of McDonald's is that they don't fight battles they can't win. When something doesn't work, they just dump it and they move on. Which is why I say you downgrade a stock like McDonald's at your own peril.' While we acknowledge the potential of MCD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Speranza Therapeutics and Sunshine Labs Announce Strategic Global Partnership to Expand Access to Life-Saving Harm Reduction Solutions
BOCA RATON, Fla. and TORONTO, June 25, 2025 /PRNewswire/ -- Speranza Therapeutics is proud to announce a strategic partnership with Sunshine Labs, a global leader in harm reduction, safer supply, and science-backed therapeutic innovation. This groundbreaking collaboration is a significant milestone in expanding access to clinically effective medical devices, pharmaceuticals, and harm reduction tools across the United States and key international markets. Sunshine Labs, headquartered in Canada and operating under Health Canada's Controlled Drugs and Substances Act, is at the forefront of transforming how controlled substances are regulated, studied, and administered. Through its wholly owned subsidiary, Oryx Biomed, Sunshine Labs delivers pharmaceutical-grade treatments and research-ready substances to four continents — including the United Kingdom, Great Britain, Northern Ireland, Australia, and European Union member states. Together, Speranza Therapeutics and Sunshine Labs will work to equip providers, clinicians, and researchers with innovative solutions that address addiction, mental health challenges, and overdose prevention. Key areas of collaboration include: Medical Devices – Including Speranza's ST Genesis Neurostimulation Device for Detox, and Sunshine Labs' advanced Naloxone delivery system, designed to support rapid response in overdose scenarios. Psychedelics for Therapeutic Use – Supporting ongoing clinical trials and research focused on PTSD, substance use disorder, and treatment-resistant mental health conditions. Compounding Pharmacy Services – Delivering personalized, high-quality treatment formulations for complex psychiatric and behavioral health needs. Pharmaceutical-grade Treatments – All products are manufactured to the highest cGMP and euGMP standards, ensuring quality, consistency, and compliance across global markets. Note: While Sunshine Labs produces pharmaceutical-grade controlled substances for research and approved medical use in select international jurisdictions, distribution and use in the United States will remain compliant with all applicable U.S. regulatory guidelines. "This partnership represents a shared mission," said Donovan Edwards, CEO of Sunshine Labs. "Speranza and Sunshine Labs are aligned in our commitment to disruptive innovation and compassionate care. Together, we are equipping providers and researchers with safer, science-based tools to meet today's public health challenges head-on." Speranza Therapeutics brings deep expertise in U.S. regulatory landscapes and a strong track record in advancing medical device innovation. Known for its pioneering work in addiction medicine and pain management, Speranza is committed to eliminating barriers to treatment access — especially for patients with chronic or underserved conditions. "We're honored to join forces with Sunshine Labs," said Sal J. Rafanelli, President and CEO of Speranza Therapeutics. "Their leadership in regulatory innovation and global distribution is unmatched. We are especially excited about expanding access to the ST Genesis Device through this partnership — not only in Canada, but also in the UK, Great Britain, Northern Ireland, Australia, and throughout the European Union. Together, we are driving meaningful clinical outcomes for those who need them most." This strategic alliance reflects a mutual commitment to clinical excellence, global collaboration, and a future where harm reduction and mental health care are accessible, evidence-based, and stigma-free. About Speranza Therapeutics Speranza Therapeutics is a medical device and pharmaceutical company that is dedicated to making meaningful, more efficient and cost-effective changes in delivering medical devices and drugs to patients in the United States. Their success is the collective result of visionary leaders and dedicated clinicians focused on disrupting the norm, improving care, and making an important difference in the lives of patients with complex medical conditions. Their guiding principle is simple: to remove the inherent challenges in delivering treatment to patients in need through proven, clinically effective therapeutics and technology. For more information, contact our Marketing Manager Lauren Saccone, lsaccone@ View original content to download multimedia: SOURCE Speranza Therapeutics Sign in to access your portfolio
